Immunomodulation by intravenous omega-3 fatty acid treatment in older subjects hospitalized for COVID-19: A single-blind randomized controlled trial
Clin Transl Med
.
2022 Sep;12(9):e895.
doi: 10.1002/ctm2.895.
Authors
Hildur Arnardottir
1
,
Sven-Christian Pawelzik
1
,
Philip Sarajlic
1
,
Alessandro Quaranta
2
,
Johan Kolmert
2
3
,
Dorota Religa
4
,
Craig E Wheelock
2
3
5
,
Magnus Bäck
1
Affiliations
1
Department of Medicine Solna, Karolinska Institutet, Theme Heart, Vessels, and Neuro, Karolinska University Hospital, Stockholm, Sweden.
2
Division of Physiological Chemistry 2, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden.
3
The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
4
Department of Neurobiology, Karolinska Institutet and Theme Ageing, Karolinska University Hospital, Stockholm, Sweden.
5
Department of Respiratory Medicine and Allergy, Karolinska University Hospital, Stockholm, Sweden.
PMID:
36121173
PMCID:
PMC9484265
DOI:
10.1002/ctm2.895
No abstract available
Publication types
Letter
Randomized Controlled Trial
MeSH terms
Administration, Intravenous
Aged
COVID-19 Drug Treatment*
Fatty Acids, Omega-3* / therapeutic use
Humans
Immunomodulation
Single-Blind Method
Substances
Fatty Acids, Omega-3